Cardiovascular, kidney, and metabolic conditions have each been linked to hearing outcomes in prior literature. This study tested whether an integrated cardiovascular-kidney-metabolic (CKM) syndrome stage—operationalized from ascertainable domains of the 2026 AHA/ACC/ADA/ASN guideline—tracks objective hearing sensitivity in older adults.
The primary hypothesis was that advancing CKM syndrome stage would be associated with progressively poorer hearing as measured by audiometry.
The analysis used publicly available data from the National Health and Nutrition Examination Survey (NHANES) 2017–March 2020 pre-pandemic release. The analytic sample comprised adults aged 70–79 years. CKM syndrome Stages 0–4 were derived from guideline domains that could be ascertained in NHANES, including laboratory measures such as HbA1c and design-valid fasting plasma glucose criteria for dysglycemia.
Details about exact operational criteria for each stage as implemented were described by the authors; the source reports that stages were mapped using available NHANES variables consistent with the referenced guideline domains.
The primary hearing outcome was the bilateral pure-tone average at 0.5, 1, 2, and 4 kHz (PTA4). Analyses used survey-weighted models to account for NHANES sampling design. Models adjusted for potential confounders: age, sex, race/ethnicity, education, smoking status, and both occupational and nonoccupational noise exposure.
The primary CKM stage analysis included 285 participants distributed across stages as follows: Stage 0, n=1; Stage 1, n=18; Stage 2, n=103; Stage 3, n=65; Stage 4, n=98. An omnibus five-stage Wald test assessed overall differences in adjusted mean PTA4 across stages.
Planned pairwise contrasts and additional robustness tests were conducted. Multiplicity was addressed using Holm adjustment for multiple tests when applicable.
The five-stage omnibus Wald test was statistically significant (F(4,25)=21.405, p=9.01e-8). However, interpretation is constrained by the fact that Stage 0 contained only one participant. Adjusted mean bilateral PTA4 values reported for Stages 0–4 were nonmonotonic: 9.49, 24.3, 31.0, 29.0, and 33.4 dB HL respectively.
Because the lowest stage cell was effectively empty for inference, the global significance did not translate into a clear progressive stage effect across clinically relevant stages.
Planned contrasts focusing on Stage 2 versus Stage 3 and Stage 4, and other comparisons, were examined. After Holm multiplicity adjustment none of the planned Stage 2–4 contrasts remained statistically significant. A robustness analysis restricted to Stages 2–4 did not demonstrate significant heterogeneity across those stages (p=0.197), which argues against a consistent progressive pattern among the populated stages.
In addition to categorical stage analyses, the authors evaluated nine continuous CKM-related measures for associations with PTA4. Multiplicity across these nine tests was handled with the Holm adjustment. Only one measure retained statistical significance after adjustment: waist circumference.
The adjusted association for waist circumference was reported as an increase in bilateral PTA4 of 1.57 dB HL per 10 cm greater waist circumference (95% CI, 0.74–2.39; adjusted p=0.00547). A post-hoc spline diagnostic for nonlinearity in the waist circumference–PTA4 relationship did not show clear evidence of nonlinearity (p=0.128).
The authors note that although the association was statistically significant after multiplicity adjustment, its clinical significance at the individual level remains uncertain.
The study planned component-by-stage interaction models, but the five-stage interaction models were not estimable because Stage 0 contained only a single participant. Among Stages 2–4, six primary interaction tests were performed and none met the Holm-adjusted significance threshold.
Other limitations relevant to interpretation that are evident from the report include the small overall analytic sample (n=285) in this age band and sparse cell counts in lower stage categories, which constrained some comparisons and model estimation.
The primary hypothesis that hearing sensitivity as measured by PTA4 worsens progressively with advancing CKM syndrome stage was not supported by the available NHANES data for adults aged 70–79 years. Although the omnibus five-stage test was statistically significant, the presence of only one participant in Stage 0 and nonmonotonic adjusted means limit clinical interpretation.
Analyses confined to Stages 2–4 did not support a stage-progression pattern. A secondary finding was a small but statistically robust association between waist circumference and PTA4 after multiplicity adjustment; the authors caution that the individual-level clinical importance of this magnitude of change is unclear.
Readers should note this work is a preprint and has not undergone peer review; the authors explicitly state it should not be used to guide clinical practice.
The analysis used deidentified, publicly available NHANES 2017–March 2020 data from the U.S. Centers for Disease Control and Prevention, National Center for Health Statistics. Study-planning materials were made available on the Open Science Framework at the DOI reported by the authors. The preprint declares no competing interests and confirms adherence to relevant ethical guidelines; because only public deidentified data were used, no additional IRB approval was required according to the authors.